Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098021 | 0.83 | CA12 (0.52) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL2096675 | 0.83 | LTA4H (0.52) | TSHRCA12CA1CA2CA7 | |
| 1,4-Diethoxybenzene SCHEMBL9651064 | 0.81 | NQO1 (0.70) | NQO1TDP1TSHRPARP10CA12 | |
| 1,4-Diethoxybenzene SCHEMBL28186701 | 0.80 | NQO1 (1.00) | NQO1TDP1TSHRPARP10CA12 | |
| 1,4-Diethoxybenzene SCHEMBL124015 | 0.80 | NQO1 (1.00) | NQO1TDP1TSHRPARP10CA12 | |
| SCHEMBL8142070 | 0.80 | CA2 (0.32) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2094016 | 0.79 | NR5A1 (0.56) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL2095000 | 0.79 | TP53 (0.53) | NQO1TDP1TSHRLTA4HLMNA | |
| SCHEMBL910859 | 0.79 | NQO1 (0.67) | NQO1TDP1TSHRPARP10CA12 | |
| SCHEMBL7166937 | 0.78 | NQO1 (0.58) | NQO1TDP1TSHRPARP10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160396-B1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2476689-B1 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9067961-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2476689-A1 | Thiocarbon-protecting groups for RNA synthesis | Agilent Technologies, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8202983-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2160396-A2 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | Agilent Technologies, Inc. (US) | 2010-03-10 | — | — | EP | disclosed |
| US-5387596-A | Treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 1995-02-07 | — | — | US | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0454501-A2 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | Sankyo Company Limited (JP) | 1991-10-30 | — | — | EP | disclosed |
| EP-0180897-B1 | 5-FLUOROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-07 | — | — | EP | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | NSUN3, NSUN2, TRDMT1 | NQO1 694/4885TDP1 434/4885TSHR 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.